Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 5/20 | 0.58 |
| ▸ | CD274 | Q9NZQ7 | 9/20 | 0.38 |
| ▸ | PDCD1 | Q15116 | 7/20 | 0.38 |
| ▸ | VSIR | Q9H7M9 | 5/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PDCD1LG2 | Q9BQ51 | 2/20 | 0.33 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.32 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17826152 | 0.89 | ATR (0.56) | ATR | |
| SCHEMBL16420587 | 0.89 | ATR (0.73) | ATRVSIR | |
| SCHEMBL16420536 | 0.89 | ATR (0.56) | ATRSMN1; SMN2 | |
| SCHEMBL16424903 | 0.84 | ATR (0.81) | ATR | |
| SCHEMBL17826171 | 0.83 | ATR (0.41) | ATRCD274PDCD1VSIRSMN1; SMN2 | |
| SCHEMBL16420684 | 0.74 | ATR (0.43) | ATR | |
| SCHEMBL16424850 | 0.73 | ATR (1.00) | ATR | |
| SCHEMBL16424870 | 0.73 | ATR (0.79) | ATR | |
| SCHEMBL18177419 | 0.73 | ATR (0.47) | ATR | |
| SCHEMBL17826566 | 0.73 | ATR (0.79) | ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365557-B2 | Substituted pyrazin-2-amines as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-06-14 | — | — | US | disclosed |
| US-20150031661-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031661-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, MAP3K5 | ATR 1/4885CD274 3796/4885PDCD1 1734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.